Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

Event
ReportedContract

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 13, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BJDX
Bearish
high confidence
Mentioned
$BJDX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BJDXBearishMed
01

Why it matters

The filing reveals modest cash reserves, ongoing burn, and a need for financing, which may pressure the stock unless new capital is raised.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; relevance driven by cash‑runway concerns and upcoming FDA submission.

03

What to watch

Potential revenue from upcoming FDA 510(k) submission and government contract with Lovell could improve outlook if approved.

Relevance 7/10Novelty 7/10Timing: immediate filing today

Background

Bluejay Diagnostics is a Nasdaq‑listed developer of rapid IL‑6 testing for sepsis, reporting its Q3 2026 financials and operational milestones.

Company-level read

Ticker impact

$BJDXBearishHigh confidence
Context

Bluejay Diagnostics filed an 8‑K reporting Q3 2026 results, cash of $7.38 M and a need for additional financing through Q2 2027.

Expected impact

likely pressure as investors price in cash‑burn and financing risk

Evidence & confidence

Micro‑cap with $7.38 M cash and $5.09 M operating burn signals near‑term liquidity concerns; no new funding disclosed.

Market effects

Highlights financing challenges for early‑stage diagnostic companies developing FDA‑cleared tests.

Limited to U.S. biotech micro‑caps; no broader regional effect.

Low; the news is company‑specific without macro implications.

Counterpoint

If the company secures a strategic partnership or grant, cash concerns could be mitigated, offering upside.

Key entities

  • Bluejay Diagnostics, Inc.

    NASDAQ‑listed medical diagnostics firm developing the Symphony platform.

  • Neil Dey

    President and CEO of Bluejay Diagnostics.

Related articles

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 For Immediate Release Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock. SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Towar

$BJDXMedAI 8/10

Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock

Bluejay Diagnostics (NASDAQ:BJDX) announced baseline clinical data from its SYMON-II study, evaluating IL-6 as a biomarker for 28-day mortality risk in sepsis patients. The study included 777 patients, with an 18% mortality rate. The company aims to use this data to support a regulatory submission for its Symphony IL-6 Test, which is not yet FDA-approved.